These results of hepcidin downregulation in liver cancers were verified using another two datasets derived from cDNA microarray assay (37, 38), which showed hepcidin downregulation about 43-47 folds in HCC tissues compared to benign liver tissues (Figures 1B, C), similar to previous reports (11, 12). The gene discussed is HAMP; the disease is hepatocellular carcinoma.